Development and Validation of an Improved Pathological Nodal Staging System for Urothelial Carcinoma of the Bladder

被引:5
|
作者
Patel, Devin N. [1 ]
Luu, Michael [2 ]
Zumsteg, Zachary S. [2 ,3 ]
Daskivich, Timothy J. [1 ]
机构
[1] Cedars Sinai Med Ctr, Dept Surg, Div Urol, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA
[3] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA
来源
EUROPEAN UROLOGY ONCOLOGY | 2019年 / 2卷 / 06期
关键词
Bladder cancer; Nodal staging; Prognosis; RADICAL CYSTECTOMY; PELVIC LYMPHADENECTOMY; EXTERNAL VALIDATION; CANCER PATIENTS; IMPACT; SURVIVAL; DISCREPANCY; METASTASES; DISSECTION; PROGNOSIS;
D O I
10.1016/j.euo.2018.12.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Current pathological nodal staging for bladder cancer is based on lymph node (LN) location but not on the number of positive LNs. Objective: We sought to improve prognostic classification by creating a novel staging system incorporating positive LN burden. Design, setting, and participants: We sampled 12 515 patients with muscle-invasive bladder cancer (MIBC) from the National Cancer Database (NCDB) and 5928 MIBC patients from the Surveillance, Epidemiology, and End Results (SEER) database for our development and validation cohorts, respectively. Outcome measurements and statistical analysis: Multivariable Cox proportional hazards analysis with restricted cubic splines was used to assess the association between the number of metastatic LNs and overall mortality (OM). A novel staging system was derived by recursive partitioning analysis (RPA) in NCDB and was validated in SEER by assessing discrimination (Harrel's c-index) and calibration (mean absolute prediction error). Results and limitations: Mortality risk increased continuously with more metastatic LNs; the effect was most pronounced up to four LNs (hazard ratio [HR] 1.17, 95% confidence interval [CI] 1.12-1.22) and attenuated beyond four nodes (HR 1.03, 95% CI 1.02-1.05). RPA generated a novel staging system predicting mortality by metastatic nodal number with cutpoints at zero (reference), one (HR 1.57, 95% CI 1.46-1.69), two to three (HR 2.03, 95% CI 1.88-2.19), four to seven (HR 2.46, 95% CI 2.25-2.70), and more than seven (HR 3.83, 95% CI 3.38-4.33) positive LNs. Location of LN involvement was not a significant predictor of OM. In external validation, the novel staging system showed good risk discrimination (optimism corrected c-index 0.677, 95% CI 0.672-0.682) and calibration (mean absolute prediction error 0.011 for 5-yr OM). Results are limited by development and validation using secondary data. Conclusions: The number of metastatic LNs predicts mortality better than LN location and may improve pathological nodal staging in MIBC. Patient summary: This retrospective study found that the number of metastatic lymph nodes more accurately predicts survival than the location of metastatic lymph nodes in patients with muscle-invasive bladder cancer. This finding argues for change to the current bladder cancer staging system. (C) 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:656 / 663
页数:8
相关论文
共 50 条
  • [1] Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation
    M. Gierth
    H. M. Fritsche
    H. Buchner
    M. May
    A. Aziz
    W. Otto
    C. Bolenz
    L. Trojan
    E. Hermann
    A. Tiemann
    S. C. Müller
    J. Ellinger
    S. Brookman-May
    C. G. Stief
    D. Tilki
    P. Nuhn
    T. Höfner
    M. Hohenfellner
    A. Haferkamp
    J. Roigas
    M. Zacharias
    W. F. Wieland
    H. Riedmiller
    S. Denzinger
    P. J. Bastian
    M. Burger
    [J]. World Journal of Urology, 2014, 32 : 365 - 371
  • [2] Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation
    Gierth, M.
    Fritsche, H. M.
    Buchner, H.
    May, M.
    Aziz, A.
    Otto, W.
    Bolenz, C.
    Trojan, L.
    Hermann, E.
    Tiemann, A.
    Mueller, S. C.
    Ellinger, J.
    Brookman-May, S.
    Stief, C. G.
    Tilki, D.
    Nuhn, P.
    Hoefner, T.
    Hohenfellner, M.
    Haferkamp, A.
    Roigas, J.
    Zacharias, M.
    Wieland, W. F.
    Riedmiller, H.
    Denzinger, S.
    Bastian, P. J.
    Burger, M.
    [J]. WORLD JOURNAL OF UROLOGY, 2014, 32 (02) : 365 - 371
  • [3] Development and Validation of an Improved Pathological Nodal Staging System in Men with Prostate Cancer
    Daskivich, Timothy J.
    Luu, Michael
    Freedland, Stephen J.
    Sandler, Howard
    Spratt, Daniel E.
    Zumsteg, Zachary S.
    [J]. JOURNAL OF UROLOGY, 2022, 207 (03): : 581 - 591
  • [4] Development and Validation of an Improved Pathological Nodal Staging System in Men with Prostate Cancer EDITORIAL COMMENT
    Karnes, R. Jeffrey
    [J]. JOURNAL OF UROLOGY, 2022, 207 (03): : 591 - 591
  • [5] ASSESSMENT OF THE 2002 AJCC NODAL STAGING OF BLADDER UROTHELIAL CARCINOMA
    Patel, Sanjay
    Barocas, Daniel
    Cookson, Michael
    Clark, Peter
    Penson, David
    Smith, Joesph
    Chang, Sam
    [J]. JOURNAL OF UROLOGY, 2010, 183 (04): : E400 - E401
  • [6] External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study
    Xylinas, Evanguelos
    Kluth, Luis
    Rieken, Malte
    Roupret, Morgan
    Al Awamlh, Bashir Al Hussein
    Clozel, Thomas
    Sun, Maxine
    Karakiewicz, Pierre I.
    Gonen, Mithat
    Shariat, Shahrokh F.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (01) : 33.e21 - 33.e26
  • [7] CLINICAL AND PATHOLOGICAL NODAL STAGING SCORE FOR UROTHELIAL CARCINOMA OF THE BLADDER ARE VALID DECISION TOOLS FOR RISK ASSESSMENT AND CLINICAL DECISION-MAKING: AN EXTERNAL VALIDATION
    Gierth, Michael
    Fritsche, Hans Martin
    Buchner, Hannes
    May, Matthias
    Aziz, Attiqullah
    Otto, Wolfgang
    Bolenz, Christian
    Trojan, Lutz
    Hermann, Edwin
    Tiemann, Arne
    Mueller, Stefan C.
    Ellinger, Joerg
    Brookmann-May, Sabine
    Stief, Christian G.
    Tilki, Derya
    Nuhn, Philipp
    Hoefner, Thomas
    Hohenfellner, Markus
    Haferkamp, Axel
    Roigas, Jan
    Zacharias, Mario
    Wieland, Wolf F.
    Riedmiller, Hubertus
    Denzinger, Stefan
    Bastian, Patrick J.
    Burger, Maximilian
    [J]. JOURNAL OF UROLOGY, 2013, 189 (04): : E379 - E379
  • [8] DEVELOPMENT AND EXTERNAL VALIDATION OF A PATHOLOGICAL NODAL STAGING SCORE FOR PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA
    Rieken, Malte
    Boorjian, Stephen
    Kluth, Luis
    Xylinas, Evanguelos
    Capitanio, Umberto
    Briganti, Alberto
    Thompson, R. Houston
    Leibovich, Bradley
    Krabbe, Laura-Maria
    Margulis, Vitaly
    Raman, Jay
    Regelman, Mikhail
    Klatte, Tobias
    Bachmann, Alexander
    Karakiewicz, Pierre
    Roupret, Morgan
    Lee, Richard
    Goenen, Mithat
    Shariat, Shahrokh
    [J]. JOURNAL OF UROLOGY, 2015, 193 (04): : E797 - E797
  • [9] Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma
    Malte Rieken
    Stephen A. Boorjian
    Luis A. Kluth
    Umberto Capitanio
    Alberto Briganti
    R. Houston Thompson
    Bradley C. Leibovich
    Laura-Maria Krabbe
    Vitaly Margulis
    Jay D. Raman
    Mikhail Regelman
    Pierre I. Karakiewicz
    Morgan Rouprêt
    Mohammad Abufaraj
    Beat Foerster
    Mithat Gönen
    Shahrokh F. Shariat
    [J]. World Journal of Urology, 2019, 37 : 1631 - 1637
  • [10] Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma
    Rieken, Malte
    Boorjian, Stephen A.
    Kluth, Luis A.
    Capitanio, Umberto
    Briganti, Alberto
    Thompson, R. Houston
    Leibovich, Bradley C.
    Krabbe, Laura-Maria
    Margulis, Vitaly
    Raman, Jay D.
    Regelman, Mikhail
    Karakiewicz, Pierre I.
    Roupret, Morgan
    Abufaraj, Mohammad
    Foerster, Beat
    Gonen, Mithat
    Shariat, Shahrokh F.
    [J]. WORLD JOURNAL OF UROLOGY, 2019, 37 (08) : 1631 - 1637